Eli Lilly shares slide after a bearish analyst call — here’s our view
Eli Lilly shares are down 6% Tuesday and on pace for their worst day since February after an HSBC downgrade. The crux of HSBC’s call: Wall Street is too optimistic about the size of the GLP-1 obesity market. The firm’s analysts project it to be between $80 billion and $120 billion in 2032, compared with…